Another research on a mouse model demonstrated an improvement in the delivery of anticancer agents and a significant increase in the median survival time in patients with tumors, including glioma and HER2+ breast cancer with brain metastasis [192]. This evidence concerns the gene ERBB2 and breast carcinoma.